Latest Amylin Stories
SAN DIEGO, Oct. 12, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the third quarter of 2011 on Wednesday, October 19, 2011 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the third quarter of 2011. The call will be webcast live through the "Investors" section of Amylin's...
SAN DIEGO, Sept. 7, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, September 14, 2011 at 1:35 p.m. ET / 10:35 a.m. PT in New York. Daniel M. Bradbury, president and chief executive officer, Amylin Pharmaceuticals, will provide a corporate overview. The presentation will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and a recording...
SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., Aug. 10, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the companies' BYDUREON(TM) (exenatide extended-release for injectable suspension) resubmission. The FDA has categorized it as a Class 2 resubmission requiring up to six months for review and assigned a new Prescription Drug...
A newly-identified protein may hold the key to keeping appetite and blood sugar in check, according to a study by York University researchers.Suraj Unniappan, associate professor in York's Department of Biology, Faculty of Science & Engineering, is delving into the metabolic effects of a protein called nesfatin-1, abundantly present in the brain. His studies found that rats administered with nesfatin-1 ate less, used more stored fat and became more active. In addition, the protein...
SAN DIEGO, Aug. 4, 2011 /PRNewswire/ -- OSAKA, Japan, Aug. 5, 2011 -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that they are discontinuing development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity that comprises pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin. The joint decision was based on a commercial...
When normal proteins form protein clumps in the body, then alarm bells start ringing. Such clumps, called "amyloids," are closely associated with Alzheimer's disease and type 2 diabetes, formerly called adult-onset diabetes. If doctors knew how these proteins form clumps, then they might be able to treat such diseases more efficiently. The physicist Adrian Keller and his colleagues at the Helmholtz-Zentrum Dresden-Rossendorf and the university in Aarhus, Denmark, have succeeded in taking a...
SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., July 28, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the companies have submitted their reply to a complete response letter issued in October 2010 by the U.S. Food and Drug Administration (FDA) regarding BYDUREON(TM) (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes. The companies...
SAN DIEGO, July 26, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended June 30, 2011. Total revenue was $158.1 million for the quarter ended June 30, 2011, which included net product sales of $154.8 millionNon-GAAP operating loss was $1.7 million, compared to $7.4 million for the same period in 2010 GAAP net loss was $31.4 million, or $0.22 per share, compared to $44.2 million, or $0.31 per share, for the same period in...
SAN DIEGO, July 19, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the second quarter of 2011 on Tuesday, July 26, 2011 at 8:30 a.m. ET/5:30 a.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date pre-market, Amylin will release financial results for the second quarter of 2011. The call will be webcast live through the "Investors" section of Amylin's corporate...
New animal research demonstrates mechanisms that are involved in suppressing food intake and preventing obesity with exerciseResearch to be presented at the upcoming annual meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior, finds that alterations of meal-related gut hormone signals may contribute to the overall effects of exercise to help manage body weight.Regular exercise is important in...
